Last reviewed · How we verify
Tomudex
Tomudex is a Small molecule drug developed by AstraZeneca. It is currently in Phase 2 development.
Raltitrexed is a small molecule inhibitor of thymidylate synthase used in cancer chemotherapy. It has been studied in clinical trials for various conditions, including non-resectable hepatocellular carcinoma, colorectal cancer, and advanced gastric cancer.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
AstraZeneca is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Tomudex |
|---|---|
| Sponsor | AstraZeneca |
| Target | Folate receptor beta, Folate transporter 1, Proton-coupled folate transporter |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Short Neoadjuvant Hemithoracic IMRT for MPM (PHASE1, PHASE2)
- Raltitrexed in HIPEC (PHASE1)
- Effects of HIPEC on Postoperative Bowel Motility and Complications
- A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer (PHASE1)
- QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT (PHASE2)
- TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma (NA)
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer (PHASE2)
- DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tomudex CI brief — competitive landscape report
- Tomudex updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Tomudex
What is Tomudex?
Who makes Tomudex?
What development phase is Tomudex in?
What does Tomudex target?
Related
- Target: All drugs targeting Folate receptor beta, Folate transporter 1, Proton-coupled folate transporter
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing